Role of clinical, patient-reported outcome and medico-economic studies in the public hospital drug formulary decision-making process: results of a European survey

Over the past 20 years, drug information has grown rapidly, but little is known of its actual use in hospital decision-making. To describe the role of clinical studies (CS), patient-reported outcome studies (PROS) and medico-economic studies (MES) in public hospital drug formulary decision-making. A...

Full description

Saved in:
Bibliographic Details
Published in:Health policy (Amsterdam) 2005-02, Vol.71 (2), p.205-212
Main Authors: Haslé-Pham, Elodie, Arnould, Benoit, Späth, Hans-Martin, Follet, Alain, Duru, Gérard, Marquis, Patrick
Format: Article
Language:English
Subjects:
Clinical studies
Clinical Trials as Topic
Data Collection
Decision making
Decision Making, Organizational
Drug formulary
Drugs
Europe
Formularies as Topic
Health
Health administration
Health policy
Hospitals
Hospitals, Public - organization & administration
Medico-economics
Patient-reported outcome studies
Patients
Policy studies
Self Disclosure
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Over the past 20 years, drug information has grown rapidly, but little is known of its actual use in hospital decision-making. To describe the role of clinical studies (CS), patient-reported outcome studies (PROS) and medico-economic studies (MES) in public hospital drug formulary decision-making. A postal survey was conducted in 400 randomly selected public hospitals stratified by country (France, Germany, The Netherlands and the United Kingdom) and profession (doctor or pharmacist). The participation rate was 78% (143 doctors and 169 pharmacists), and the response rate 44%. Responders were generally interested in CS (86%), PROS (71%) and MES (71%). They reported high but unmet expectations concerning information available on PROS and MES, the methodology of these studies and interpretation of the results. To increase the impact of PROS and MES, we suggest training decision-makers in the study methodology and provide them with support of health and economic experts.
ISSN:0168-8510
1872-6054
DOI:10.1016/j.healthpol.2004.08.007